Recurrent hepatic encephalopathy precipitated by urinary tract infection in patient with liver cirrhosis: a case report
Keywords:Hepatic encephalopathy, Liver cirrhosis, Infection
Liver cirrhosis is a chronic liver injury marked by necro-inflammation and fibrogenesis. It is associated with several life-threatening complications. Hepatic encephalopathy remains to be one of the most debilitating complication of liver cirrhosis. The occurrence of hepatic encephalopathy may be directly related to endogenous worsening of liver function or occurs in the presence of specific precipitating factor. Infection such as urinary tract infection is a common precipitant of hepatic encephalopathy. We present a case of 66 year old female with recurrent hepatic encephalopathy in hepatitis B-related liver cirrhosis precipitated by urinary tract infection. Rapid and precise recognition of precipitating factor in hepatic encephalopathy is very substantial for implementation of preventive measures and optimal treatment plan in order to achieve better outcomes in liver cirrhosis patient.
Qiao J. Occurrence, diagnosis and management of hepatic fibrosis and cirrhosis: An updated literature review. Arch Hepat Res. 2019;5(1):22-6.
Alaqaili HI, Al-Juraysan AI, Hawsawi RMA, Abuzaid FA, Alharbi MA, Mughallis AEA. Review on liver cirrhosis complications and treatment. Egypt J Med. 2017;69(8):3092-103.
GBD 2017 cirrhosis collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245-66.
Montagnese S, Russo FP, Amodio P, Burra P, Gasbarrini A, Loguercio C, et al. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian association for the study of the liver. Digest Liver Dis. 2019;51:190-205.
Yuan L, Chuah S, Yang S, Liang C, Wu C, Tai W, et al. Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis. PLoS ONE. 2018;13(5):1-14.
Ferenci P. Hepatic encephalopathy. Gastroenterology Report. 2017;5(2):138-47.
Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs. 2019;79(1):S5-9.
European association for the study of the liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-60.
Piotrowski D, Boron-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis–prophylaxis and treatment. Adv Med Sci. 2017;62:345-56.
Urinary tract infection; catheter associated urinary tract infection (CAUTI) and non-catheter associated urinary tract infection (UTI) and other urinary system infection (USI) events. Available at: https://www.cdc. gov/nhsn/pdfs/pscmanual/7psccauticurrent.pdf. Accessed on 4 March 2021.
Archambaud C, Derré-Bobillot A, Lapaque N, Rigottier-Gois L, Serror P. Intestinal translocation of enterococci requires a threshold level of enterococcal overgrowth in the lumen. Sci Rep. 2019;9:8926-38.
Sandhu N, Navarro V. Drug-induced liver injury in GI practice. Hepatol Comm. 2020;4(5):631-45.
Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol. 2020; 73:1526-47.
Bacon BR. Cirrhosis and its complication. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, eds. Harrison’s principle of internal medicine. 20th ed. New York: McGraw-Hill; 2018:2405-14.
Butterworth RF, McPhail MJW. L-Ornithine L-Aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses. Drugs. 2019;79 (1):S31-7.